NEW YORK (Reuters) - Pfizer Inc agreed to pay $35 million to 41 U.S. states and Washington, D.C. to settle claims that its Wyeth unit illegally marketed the drug Rapamune, and encouraged doctors and hospitals to prescribe it for off-label uses.
The settlement was announced on Wednesday, just over one year after Pfizer agreed in July 2013 to pay $490.9 million to resolve U.S. Department of Justice claims over the marketing of the drug.
22:33 Allergan to pay $15 million over failing to disclose merger talks17
21:40 HP Enterprise to buy cloud software company SimpliVity17
19:08 U.S. indicts three Takata executives, fines company $1 billion in faulty air bag scandal16
18:18 U.S. government charges Takata over handling of defective air bags14